Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LOTENSIN HCT

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

Standard Dose
5MG;6.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LOTENSIN HCT is listed in Drugs@FDA under application 020033 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE Form and strength TABLET;ORAL - 5MG;6.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALIDUS PHARMS Submission history Latest submission status date: 2020-08-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview LOTENSIN HCT is listed in Drugs@FDA under application 020033 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE Form and strength TABLET;ORAL - 5MG;6.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALIDUS PHARMS Submission history Latest submission status date: 2020-08-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
LOTENSIN HCT (BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE) | Drug Monograph | MedicHelpline